00.111000.1110 A375A375R2 Vemurafenib (µM) BRAF (Full Length) p61-BRAF Isoform pMEK pERK Tubulin Supplementary Figure S1 0.004.01.040.01.030.10.313100.01.11.

Slides:

Advertisements

Similar presentations

Supplementary Table 1 A. B. CI simulations display synergism (CI 1) for the entire spectrum of effect levels (Fa) in the combination of NFV and BZ (right.

Advertisements

Supplementary Figure 1: Co-treatment with SAHA and PLX4720 increases the level of a ~50kD fragment of PARP. Whole cell lysates from MM200 and Sk-Mel-28.

Supplemental Figure 1: Chemical structures of fludioxonil and fenhexamid. FludioxonilFenhexamid.

Supplementary Figure S1

NPV-BEZ235PKI-587 GDC-0980PD Supplemental Figure S1 Structures of Inhibitors NVP-BEZ235; PKI-587; GDC-0980 and PD

P247. Figure 9-1 p248 Figure 9-2 p251 p251 Figure 9-3 p253.

P-ERK β-tubulin VSShh + cyclopamine Supplementary Figure ESM 1a ERK MAP Kinase activity is not affected by Shh pathway activity. Western blot analysis.

CAMA-1MDA-MB-361 (HER2+)HCC-1569 (HER2+)BT474 (HER2+)HS578TMDA-MB-415 (Luminal)MDA-MB-231MDA-MB-468MDA-MB-436BT20TMDA-MB N10A76NF2V76NE7T47DZR75-1MCF-7MDA-MB-453.

Figure 1 B D DOX ( μ M) C Cell Proliferation (% Con) MCF-7MCF-7/DOX DOX ( μ M) 0.03% 38.79% 0.15% 0.10% 0.20% 0.05%

Supplementary Table S1 Clinical exposure for palbociclib, fulvestrant and chemotherapeutic agents used in this study. Palbociclib (1)*Paclitaxel (2)*Doxorubicin.

Supplementary Figure S1 Cell index hours Cell index hours MiaPaca-2 cells vehicle ABTL0812 A549 cells.

A B A Stat3:Stat3 Supershift  -ST3 Free probe BP1-102 (µM) Stat3:Stat3 % of Cont Supplementary Figures Fig. S1 -

親愛的吉姆舅舅：今天吃完晚餐後，奶奶說，在家裡情況變好以前，您要我搬到城裡跟您住。奶奶有沒有跟您說，爸爸已經好久沒有工作，也好久沒有人請媽媽做衣服了？我們聽完都哭了，連爸爸也哭了，但是媽媽說了一個故事讓我們又笑了。她說：您們小的時候，她曾經被您追得爬到樹上去，真的嗎？雖然我個子小，但是我很強壯，

Farmer et al Supplementary Figure 1 KU PARP-1 IC 50 = 3.2nM KU PARP-1 IC 50 = 3.4nM KU PARP-1 IC 50 = 730nM a b

Figure1 HER2 SKBr3 PC3 A. SKBr3 cells Figure (µM) Penetratin control % of control (µM)

Date of download: 7/12/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Inhibition of the Growth of Papillary Thyroid Carcinoma.

Date of download: 9/17/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Differential Responses of Human Papillary Thyroid.

Supplementary Fig. 1 *** Cell viability (%) HepG2 3 (hr) DU145 A549 17

Supplemental Materials: Anti-apoptotic BCL-2 family proteins as 5-Azacytidine sensitizing targets and determinants of response in myeloid malignancies.

Copyright © 2007 American Medical Association. All rights reserved.

Volume 352, Issue 2, Pages (October 2014)

Supplementary Figure 1 (log fold change relative to untreated control)

A B C MDA-MB-231 OHT: h FOXM1 PLK CDC25b ERα Tubulin

MCF-7: E2 E2(-4h)+OHT E2(-4h)+ICI (h)

B c * a Supplementary Figure 1. NLRP1 knockdown suppresses tumor growth in vivo. (a) 1205Lu tumors with NLRP1 shRNA from Santa Cruz Biotechnology. (b)

Supplement 1 -Psen1 -Psen2 Dasatinib (100 nM) Hours Con

Volume 19, Issue 5, Pages (May 2011)

A Vehicle PLX8394 Normalized Protein Level

Bortezomib 1nM PU.1 GAPDH KMS12PE U266 U937 Supplemental Figure S1.

BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity by Valentina Pettirossi,

Angiogenesis Inhibitors

TNF enhances dose‐dependent cell death following doxorubicin‐induced DNA damage with minimal affect on dose‐dependent cell‐cycle arrest. TNF enhances dose‐dependent.

1A 1B Supplementary Figure 1. Parp HT29 C-Parp Gapdh LoVo

FL cells are dependent on BCL6 in a NOTCH2-dependent manner.

Volume 28, Issue 3, Pages (September 2015)

Volume 27, Issue 1, Pages (January 2015)

Figure S1 Nil + CK Nil CK C BIM BCLXL Pro-caspase 3 Cleaved caspase 3

Volume 19, Issue 10, Pages (October 2017)

Elevated expression of CD147 in patients with endometriosis and its role in regulating apoptosis and migration of human endometrial cells Aihong Jin,

UVC UVB A B Supplementary 1, Borrelli et al.

Volume 29, Issue 1, Pages (January 2016)

Supplementary Figure text

Figure 2S (Supplementary Data)

B A D C * * E F Panc-1 cells Figure S1 DNA ladder h

Supplementary figure 1 A. Ctrl PB b III Tubulin F actin Hoechst * B.

Supplementary Figure S5, Lecoeur et al.

Supplementary Figure B. 50.

Volume 28, Issue 3, Pages (September 2015)

Volume 29, Issue 3, Pages (March 2016)

Activation of Erk1/2 and Akt following unilateral ureteral obstruction

Supplementary Figure 1. A

Volume 23, Issue 5, Pages (May 2013)

Volume 20, Issue 6, Pages (December 2011)

Abemaciclib (µM) LY (µM)

Volume 21, Issue 2, Pages (October 2017)

Supplementary Figure S4

Regulated P124SMEK1 expression cannot alter p-ERK levels or sensitivity to BRAF or MEK inhibition in V600EBRAF melanoma cell lines. Regulated P124SMEK1.

T55delinsRT mutation in MEK1 is responsible for resistance to vemurafenib in M032R4 Somatic mutations present in each of these metastases, revealing that.

Volume 21, Issue 11, Pages (November 2014)

The HDAC3 inhibitor suppresses PTEN‐deficient prostate cancer growth

AMPK induces VEGF-A production by upregulating ERK signaling.

A, analysis of cytoplasmic histone-associated DNA fragmentation in LNCaP cells following 24-h cotreatment with the indicated concentrations of SFN and.

Romidepsin reduces histone deacetylase activity, induces acetylation of histones, inhibits proliferation, and activates apoptosis in immortalized epithelial.

Volume 22, Issue 5, Pages (November 2012)

Inhibition of polymerization Enhancement of polymerization

Sensor siRNAs can be used in high-order combinations.

VC KX-01 Total Src p-Y416 Src Supplementary Figure S1. KX-01 at low dose inhibited phosphorylation of Src in MDA-MB-231 xenografts.

by Dana S. Levy, Jason A. Kahana, and Rakesh Kumar

Complete Vehicle Systems.

LY elicits hyperphosphorylation of Akt.

Presentation transcript:

A375A375R2 Vemurafenib (µM) BRAF (Full Length) p61-BRAF Isoform pMEK pERK Tubulin Supplementary Figure S A375-R4 NRas Q61KA375 Vemurafenib (µM) pMEK pS338-cRaf pERK Ras Tubulin B A

Supplementary Figure S2 Vehicle Vemurafenib LY Vemurafenib

Supplementary Figure S3 A375A375-RV2 pERK Tubulin Vemurafenib (µM)

Supplementary Figure S4 DMSO 1.5  M  M M14 M14-R %G1= %S = %G2/M = %G1= %S = 2.73 %G2/M = %G1= %S = 3.81 %G2/M = %G1= %S = %G2/M = %Debris = %G1= %S = %G2/M = %Debris = %G1= %S = %G2/M = LY Relative Caspase 3 Activity (%) Log Concentration LY (nM) A375 A375-R1 M14 M14-R B A A375A375-RV1A375-RV2A375-R1A375A375-RV1A375-RV2A375-R1 Cyclin D1 siRNA Cyclin D1 ←Cyclin D2 Cleaved-PARP Tubulin C